Using Tumor Slices to Test Doxorubicin in Canine Mammary Cancer
Author Information
Author(s): Renata A Sobral, Suzana T Honda, Maria Lucia H Katayama, Helena Brentani, Mitzi M Brentani, Diogo FC Patrão, Maria Aparecida K Folgueira
Primary Institution: Faculdade de Medicina da Universidade de São Paulo
Hypothesis
Can the expression of specific gene trios predict the response of canine mammary carcinoma to doxorubicin treatment?
Conclusion
The study found that the expression of certain gene trios could not predict doxorubicin responsiveness in canine mammary tumors.
Supporting Evidence
- Nine out of 38 samples were classified as responsive to doxorubicin treatment.
- A mean reduction of 13.6% in cell number was observed upon treatment.
- Gene expression did not clearly separate responsive from non-responsive tumors.
Takeaway
The researchers wanted to see if certain genes could help predict how well a cancer treatment would work in dogs, but they found that it didn't really help.
Methodology
Tumor slices from 38 dogs were cultured with or without doxorubicin for 24 hours, and cell counts were used to determine drug responsiveness.
Limitations
The study only evaluated a short-term response to doxorubicin and did not establish a clear separation between responsive and non-responsive tumors based on gene expression.
Participant Demographics
Median age of dogs was 10.4 years; 55% were mixed breed and 18.4% were poodle.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website